Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
Thirteen anovulatory oligomenorrheic, hyperandrogenic, and normoprolactinemic women were treated with spironolactone (aldactone) throughout six consecutive menstrual cycles in a dosage of 100 to 150 mg/day. During this treatment a significant decrease in serum luteinizing hormone (LH), testosterone, prolactin, and 17-ketosteroid values were observed that were accompanied by ovulation in 11 women (85%), according to basal body temperature (BBT) and progesterone values. In addition, improvement of hirsutism was observed in 9 (70%) and restoration of regular cycles in 11 (85%) of the patients. The side effects observed were mild and did not lead to interruption of the treatment. Our data suggest that the antiandrogenic properties of spironolactone render it a suitable agent in the treatment of anovulatory, oligomenorrheic, and hyperandrogenic women.
D015068:17-Ketosteroids / Q000652:urine; D000728:Androgens / Q000097:blood*; D000858:Anovulation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000150:complications; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008599:Menstruation Disturbances / Q000188:drug therapy*; D009839:Oligomenorrhea / Q000150:complications / Q000188:drug therapy*; D011374:Progesterone / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood
D015068:17-Ketosteroids; D000728:Androgens; D013148:Spironolactone; D013739:Testosterone; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone